RT Journal Article
T1 Mediterranean diet and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition cohort.
A1 Molina-Montes, Esther
A1 Sanchez-Perez, Maria-Jose
A1 Buckland, Genevieve
A1 Bueno-de-Mesquita, H B As
A1 Weiderpass, Elisabete
A1 Amiano, Pilar
A1 Wark, Petra A
A1 Kühn, Tilman
A1 Katzke, Verena
A1 Huerta, José María
A1 Ardanaz, Eva
A1 Quirós, José Ramón
A1 Affret, Aurélie
A1 His, Mathilde
A1 Boutron-Ruault, Marie-Christine
A1 Peeters, Petra H
A1 Ye, Weimin
A1 Sund, Malin
A1 Boeing, Heiner
A1 Iqbal, Khalid
A1 Ohlsson, Bodil
A1 Sonestedt, Emily
A1 Tjønneland, Anne
A1 Petersen, Kristina En
A1 Travis, Ruth C
A1 Skeie, Guri
A1 Agnoli, Claudia
A1 Panico, Salvatore
A1 Palli, Domenico
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Freisling, Heinz
A1 Huybrechts, Inge
A1 Overvad, Kim
A1 Trichopoulou, Antonia
A1 Bamia, Christina
A1 Vasilopoulou, Effie
A1 Wareham, Nick
A1 Khaw, Kay-Tee
A1 Cross, Amanda J
A1 Ward, Heather A
A1 Riboli, Elio
A1 Duell, Eric J
AB The Mediterranean diet (MD) has been proposed as a means for cancer prevention, but little evidence has been accrued regarding its potential to prevent pancreatic cancer. We investigated the association between the adherence to the MD and pancreatic cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Over half a million participants from 10 European countries were followed up for over 11 years, after which 865 newly diagnosed exocrine pancreatic cancer cases were identified. Adherence to the MD was estimated through an adapted score without the alcohol component (arMED) to discount alcohol-related harmful effects. Cox proportional hazards regression models, stratified by age, sex and centre, and adjusted for energy intake, body mass index, smoking status, alcohol intake and diabetes status at recruitment, were used to estimate hazard ratios (HRs) associated with pancreatic cancer and their corresponding 95% confidence intervals (CIs). Adherence to the arMED score was not associated with risk of pancreatic cancer (HR high vs low adherence=0.99; 95% CI: 0.77-1.26, and HR per increments of two units in adherence to arMED=1.00; 95% CI: 0.94-1.06). There was no convincing evidence for heterogeneity by smoking status, body mass index, diabetes or European region. There was also no evidence of significant associations in analyses involving microscopically confirmed cases, plausible reporters of energy intake or other definitions of the MD pattern. A high adherence to the MD is not associated with pancreatic cancer risk in the EPIC study.
YR 2017
FD 2017-02-07
LK http://hdl.handle.net/10668/10850
UL http://hdl.handle.net/10668/10850
LA en
DS RISalud
RD Apr 18, 2025